C-393
Third Session, Fortieth Parliament,
59-60 Elizabeth II, 2010-2011
HOUSE OF COMMONS OF CANADA
BILL C-393
An Act to amend the Patent Act (drugs for international humanitarian purposes) and to make a consequential amendment to another Act
AS PASSED
BY THE HOUSE OF COMMONSMARCH 9, 2011
402158
SUMMARY
This enactment amends the Patent Act to make it easier to manufacture and export pharmaceutical products to address public health problems afflicting many developing and least-developed countries, especially those resulting from HIV/AIDS, tuberculosis, malaria and other epidemics.
Also available on the Parliament of Canada Web Site at the following address:http://www.parl.gc.ca
.vis1 {position: absolute;display:block;}
.vis2 {position: static;}
3rd Session, 40th Parliament,
59-60 Elizabeth II, 2010-2011
house of commons of canada
BILL C-393
An Act to amend the Patent Act (drugs for international humanitarian purposes) and to make a consequential amendment to another Act
Her Majesty, by and with the advice and consent of the Senate and House of Commons of Canada, enacts as follows:
R.S., c. P-4
PATENT ACT
1. Section 21.01 of the Patent Act is replaced by the following:
Purpose
21.01 The purpose of sections 21.02 to 21.16 is to facilitate access to pharmaceutical products to address public health problems afflicting many developing and least-developed countries, especially those resulting from HIV/AIDS, tuberculosis, malaria and other epidemics.
2. Section 21.02 of the Act is replaced by the following:
Definitions
21.02 The definitions in this section apply in sections 21.01 to 21.16.
“authorization”« autorisation »
“authorization” means an authorization granted under subsection 21.04(1).
“pharmaceutical product”« produit pharmaceutique »
“pharmaceutical product” means any patented product listed in Schedule 1 in, if applicable, the dosage form, the strength and the route of administration specified in that Schedule in relation to the product and any other patented product, or product manufactured through a patented process, of the pharmaceutical sector needed to address public health problems, especially those resulting from HIV/AIDS, tuberculosis, malaria and other epidemics, and includes active ingredients necessary for its manufacture and diagnostic kits needed for its use.
3. (1) Subsections 21.03(1) and (2) of the Act are replaced by the following:
Amending Schedule 1
21.03 (1) The Governor in Council may, by order, on the recommendation of the Minister and the Minister of Health, amend Schedule 1
(a) by adding the name of any patented product that may be used to address public health problems afflicting many developing and least-developed countries, especially those resulting from HIV/AIDS, tuberculosis, malaria and other epidemics and, if the Governor in Council considers it appropriate to do so, by adding one or more of the following in respect of the patented product, namely, a dosage form, a strength and a route of administration; and
(b) by removing any entry listed in it.
Amending Schedule 2
(2) The Governor in Council may, by order, on the recommendation of the Minister of Foreign Affairs, the Minister for International Trade and the Minister for International Cooperation, amend Schedule 2 to add the name of a country if the country is
(a) recognized by the United Nations as being a least-developed country; or
(b) named on the Organization for Economic Co-operation and Development's list of countries that are eligible for official development assistance.
(2) Subsection 21.03(3) of the Act is replaced by the following:
Removal from Schedule 2
(3) The Governor in Council may, by order, on the recommendation of the Minister of Foreign Affairs, the Minister for International Trade and the Minister for International Cooperation, amend Schedule 2 to remove the name of a country if the country is neither
(a) recognized by the United Nations as being a least-developed country; nor
(b) named on the Organization for Economic Co-operation and Development's list of countries that are eligible for official development assistance.
4. (1) Subsection 21.04(1) of the Act is replaced by the following:
Authorization
21.04 (1) Subject to subsection (3), the Commissioner shall, on the application of any person and on the payment of the prescribed fee, authorize the person to make, construct and use a patented invention solely for purposes directly related to the manufacture of the pharmaceutical product named in the application and to sell it for export to any country listed in Schedule 2.
(2) Paragraph 21.04(2)(c) of the Act is repealed.
(3) Paragraphs 21.04(2)(e) and (f) of the Act are repealed.
(4) Subparagraphs 21.04(3)(c)(i) and (ii) of the Act are replaced by the following:
(i) sought from the patentee or, if there is more than one, from each of the patentees, by certified or registered mail, a licence to manufacture and sell the pharmaceutical product for export to one or more of the countries listed in Schedule 2 on reasonable terms and conditions and that such efforts have not been successful, and
(ii) provided the patentee, or each of the patentees, as the case may be, by certified or registered mail, in the written request for a licence, with the information that is in all material respects identical to the information referred to in subsection (2).
(5) Paragraph 21.04(3)(d) of the Act is repealed.
(6) Section 21.04 of the Act is amended by adding the following after subsection (3):
Solemn or statutory declaration not required
(4) The solemn or statutory declaration referred to in paragraph (3)(c) is not required in the case of an application to the Commissioner for an authorization to supply the prod- uct named in the application to an eligible importing country for purposes of addressing a national emergency or other circumstances of extreme urgency in that country or for purposes of public non-commercial use, but in such cases, the Commissioner shall notify the patentee or patentees of the issuance of the compulsory licence as soon as reasonably practicable after it has been issued.
5. Section 21.05 of the Act is replaced by the following:
Form and content of authorization
21.05 The authorization must be in the prescribed form and contain the prescribed information.
Labelling requirements
21.051 The holder of an authorization shall ensure that all products manufactured under the authorization are labelled in accordance with the prescribed requirements.
6. The portion of subsection 21.16(1) of the Act before paragraph (b) is replaced by the following:
Obligation to provide copy of agreement
21.16 (1) Within fifteen days after entering into an agreement for the sale of a product to which the authorization relates, the holder of an authorization must provide by certified or registered mail, the Commissioner and the patentee, or each patentee, as the case may be, with
(a) a copy of the agreement; and
7. Schedules 2 to 4 of the Act are replaced by the schedule set out in the schedule to this Act.
CESSATION OF APPLICATION
Application of provisions maintained
8. The provisions of this Act that amend the Patent Act shall cease to apply on the day that is the tenth anniversary of the day on which this Act comes into force unless, before that day, the application of those provisions is subject to a comprehensive review by the standing committee designated by the House of Commons for that purpose, that committee recommends that they be maintained and the House of Commons approves that recommendation.
SCHEDULE 
(Section 15)
SCHEDULE 2
(Section 21.03)
Afghanistan
Afghanistan
Albania
Albanie
Angola
Angola
Antigua and Barbuda
Antigua-et-Barbuda
Argentina
Argentine
Armenia
Arménie
Bahrain, Kingdom of
Bahreïn, Royaume de
Bangladesh
Bangladesh
Barbados
Barbade
Belize
Belize
Benin
Benin
Bhutan
Bhoutan
Bolivia
Bolivie
Botswana
Botswana
Brazil
Brésil
Brunei Darussalam
Brunéi Darussalam
Bulgaria
Bulgarie
Burkina Faso
Burkina Faso
Burundi
Burundi
Cambodia
Cambodge
Cameroon
Cameroun
Cape Verde
Cap-Vert
Central African Republic
République centrafricaine
Chad
Tchad
Chile
Chili
China
Chine
Chinese Taipei
Taipei chinois
Colombia
Colombie
Comoros
Comores
Congo
Congo
Costa Rica
Costa Rica
Côte d'Ivoire
Côte d'Ivoire
Croatia
Croatie
Cuba
Cuba
Cyprus
Chypre
Czech Republic
République tchèque
Democratic Republic of the Congo
République démocratique du Congo
Djibouti
Djibouti
Dominica
Dominique
Dominican Republic
République dominicaine
Ecuador
Équateur
Egypt
Égypte
El Salvador
El Salvador
Equatorial Guinea
Guinée équatoriale
Eritrea
Érythrée
Estonia
Estonie
Ethiopia
Éthiopie
Fiji
Fidji
Former Yugoslav Republic of Macedonia
Ex-République yougoslave de Macédoine
Gabon
Gabon
Gambia
Gambie
Georgia
Géorgie
Ghana
Ghana
Grenada
Grenade
Guatemala
Guatemala
Guinea
Guinée
Guinea-Bissau
Guinée-Bissau
Guyana
Guyana
Haiti
Haïti
Honduras
Honduras
Hong Kong, China
Hong Kong, Chine
Hungary
Hongrie
India
Inde
Indonesia
Indonésie
Israel
Israël
Jamaica
Jamaïque
Jordan
Jordanie
Kenya
Kenya
Kiribati
Kiribati
Korea
Corée
Kuwait
Koweït
Kyrgyz Republic
République kirghize
Lao People's Democratic Republic
République démocratique populaire lao
Latvia
Lettonie
Lesotho
Lesotho
Liberia
Libéria
Liechtenstein
Liechtenstein
Lithuania
Lituanie
Macao, China
Macao, Chine
Madagascar
Madagascar
Malawi
Malawi
Malaysia
Malaisie
Maldives
Maldives
Mali
Mali
Malta
Malte
Mauritania
Mauritanie
Mauritius
Maurice
Mexico
Mexique
Moldova
Moldova
Mongolia
Mongolie
Morocco
Maroc
Mozambique
Mozambique
Myanmar
Myanmar
Namibia
Namibie
Nepal
Népal
Nicaragua
Nicaragua
Niger
Niger
Nigeria
Nigéria
Oman
Oman
Pakistan
Pakistan
Panama
Panama
Papua New Guinea
Papouasie-Nouvelle-Guinée
Paraguay
Paraguay
Peru
Pérou
Philippines
Philippines
Poland
Pologne
Qatar
Qatar
Romania
Roumanie
Rwanda
Rwanda
Saint Kitts and Nevis
Saint-Kitts-et-Nevis
Saint Lucia
Sainte-Lucie
Saint Vincent and the Grenadines
Saint-Vincent-et-les-Grenadines
Samoa
Samoa
Sao Tome and Principe
Sao Tomé-et-Principe
Senegal
Sénégal
Sierra Leone
Sierra Leone
Singapore
Singapour
Slovak Republic
République slovaque
Slovenia
Slovénie
Solomon Islands
Îles Salomon
Somalia
Somalie
South Africa
Afrique du Sud
Sri Lanka
Sri Lanka
Sudan
Soudan
Suriname
Suriname
Swaziland
Swaziland
Thailand
Thaïlande
Timor-Leste
Timor-Leste
Togo
Togo
Trinidad and Tobago
Trinité-et-Tobago
Tunisia
Tunisie
Turkey
Turquie
Tuvalu
Tuvalu
Uganda
Ouganda
United Arab Emirates
Émirats arabes unis
United Republic of Tanzania
République-Unie de Tanzanie
Uruguay
Uruguay
Vanuatu
Vanuatu
Venezuela
Venezuela
Yemen
Yémen
Zambia
Zambie
Zimbabwe
Zimbabwe
Published under authority of the Speaker of the House of CommonsAvailable from:Publishing and Depository ServicesPublic Works and Government Services Canada